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ABSTRACT
Progranulin (PGRN) is a growth factor implicated in
various pathophysiological processes, including wound
healing, inﬂammation, tumorigenesis, and neurodegen-
eration. It was previously reported that PGRN binds to
tumor necrosis factor receptors (TNFR) and has thera-
peutic effects in inﬂammatory arthritis (Tang et. al, in
Science 332:478–484, 2011); however, Chen et al.
reported their inability to demonstrate the PGRN-TNFR
interactions under their own conditions (Chen et. al, in J
Neurosci 33:9202–9213, 2013). A letter-to-editor was
then published by the original group in response to the
Chen et al. paper that discussed the reasons for the
latter’s inability to recapitulate the interactions. In addi-
tion, the group published follow-up studies that further
reinforced and dissected the interactions of PGRN-
TNFR. Recently, the dispute about the legitimacy of
PGRN-TNFR interactions appears to be ﬁnally settled
with independent conﬁrmations of these interactions in
various conditions by numerous laboratories. This
review presents a chronological update on the story of
PGRN-TNFR interactions, highlighting the independent
conﬁrmations of these interactions in various diseases
and conditions.
KEYWORDS progranulin, Atsttrin, TNFR, DR3, TNF-α,
TL1A
INTRODUCTION
Progranulin (PGRN), also known as granulin-epithelin pre-
cursor (GEP), proepithelin (PEPI), acrogranin, and GP88/
PC-cell derived growth factor (PCDGF), is a 593-amino-acid
autocrine growth factor. PGRN contains seven-and-a-half
repeats of a cysteine-rich motif (CX5-6CX5CCX8CCX6CC
XDX2HCCPX4CX5-6C) in the order P-G-F-B-A-C-D-E
where A-G are full repeats and P is a half-motif (Bateman
and Bennett, 2009; Jian et al., 2013a). PGRN is among the
earliest extracellular regulatory proteins still employed by
multicellular animals (Palfree et al., 2015). Originally, PGRN
was regarded as a growth factor that physiologically pro-
motes cell proliferation and wound healing (He et al., 2003).
Simultaneously, upregulated expression of PGRN was found
in many types of cancer, and PGRN was found to promote
cancer cell growth under these pathological conditions
(Diaz-Cueto et al., 2012; Frampton et al., 2012; Serrero,
2003). GRN gene mutations were found to cause fron-
totemporal dementia (Baker et al., 2006; Cruts et al., 2006)
and have been associated with other neurodegenerative
diseases, such as Parkinson’s disease, Creutzfeldt-Jakob
disease, motor neuron disease, and Alzheimer’s disease
(Baker and Manuelidis, 2003; Lopez de Munain et al., 2008;
Malaspina et al., 2001; Vercellino et al., 2011). PGRN is
considered to be a neurotropic factor as well (Van Damme
et al., 2008).
Besides its function as a growth factor and neurotropic
factor, PGRN was reported to have anti-inﬂammatory activ-
ities in multiple inﬂammatory conditions (Jian et al., 2013a).
PGRN inhibits LPS-mediated IL-6, TNF-α, and monocyte
chemoattractant protein-1 (MCP-1) cytokine release from
macrophages (Yin et al., 2010) and mitigates LPS-induced
acute lung inﬂammation (Guo et al., 2012). PGRN, as
opposed to its degraded granulin(s), blocks the TNF-α
induced respiratory burst in neutrophils (Zhu et al., 2002).
The balance between anti-inﬂammatory PGRN and pro-in-
ﬂammatory degraded granulin units is also important in
neuroinﬂammation (reviewed by Ahmed, Z, et al. (Ahmed
et al., 2007)). PGRN inhibits immune complex-mediated (IC-
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mediated) neutrophil inﬁltration in vivo and reduces activa-
tion of isolated neutrophils by ICs in vitro (Kessenbrock et al.,
2008). Although it was clear that PGRN had anti-inﬂamma-
tory effects in these various diseases, it was uncertain how
PGRN exerted these properties. The ﬁnding that PGRN
directly binds to TNFR and blocks the binding of TNF-α to its
receptors provided new insight into the molecular mecha-
nisms underlying PGRN-mediated anti-inﬂammation (Tang
et al., 2011). This review summarizes the story of PGRN-
TNFR interactions, with a special focus on the recent con-
ﬁrmations of PGRN-TNFR interactions.
DISCOVERY OF PGRN-TNFR INTERACTIONS
PGRN was ﬁrst found to bind to TNFR in a yeast two-hybrid
system when screening for PGRN-binding proteins by using
PGRN as bait (Tang et al., 2011). This unexpected interaction
was further conﬁrmed in human cells by co-immunoprecipi-
tation (Co-IP). Direct protein-protein interactions between
PGRN and TNFR were revealed in an ELISA-based solid
phase binding assay. The binding afﬁnities were measured
through the surface plasmon resonance (SPR) approach by
SensiQ (Oklahoma City, OK) and showed that PGRN
selectively binds to both TNFR1 and TNFR2, and that it binds
to TNFR2 with much higher afﬁnity than TNF-α (Jian et al.,
2013b; Tang et al., 2011). Notably, PGRN showed thera-
peutic effects in various TNF-mediated inﬂammatory arthritis
models, including collagen-induced arthritis and sponta-
neous arthritis in the TNF-transgenic model (Liu, 2011; Liu
and Bosch, 2012; Tang et al., 2011; Wei et al., 2014a).
The domains of PGRN required for binding to TNFR were
then determined through a series of PGRN deletion mutants
and three fragments composed of granulin F, A, C and their
adjacent linkerswere found to be responsible for the binding to
TNFR. These three fragments most likely mimic the trimer
structure of TNFwhenbinding toTNFR (WuandSiegel, 2011).
Based on these results, Tang et al. further generated an
engineered molecule called Atsttrin that only contained half
Grn F, A, C, and was found to still bind to TNFR. Atsttrin was
shown to have even better therapeutic effects than PGRN in
treating inﬂammatory arthritis (Tang et al., 2011). In brief, this
unexpected discovery of PGRN-TNFR interaction provided
the molecular insights into the mechanism underlying PGRN-
mediated anti-inﬂammatory activities and might present
PGRN and its engineered derivative, Atsttrin, as the next-
generation drug target for various kinds of inﬂammatory dis-
eases (Liu, 2011; Liu and Bosch, 2012; Sﬁkakis and Tsokos,
2011; Wu and Siegel, 2011).
INABILITY TO DEMONSTRATE THE INTERACTIONS
OF PGRN-TNFR BY CHEN, ET AL.
The ﬁndings that PGRN binds to TNFR and is therapeutic in
inﬂammatory arthritis stimulated the explorations of PGRN/
TNFR in many other inﬂammatory diseases and conditions
(Egashira et al., 2013; Guo et al., 2012; Huang et al., 2015;
Hwang et al., 2013; Kawase et al., 2013; Li et al., 2014; Liu et al.,
2014; Liu et al., 2015; Thurner et al., 2015; Thurner et al., 2014;
Thurner et al., 2013b; Vezina et al., 2014; Wei et al., 2014a;
Yamamoto et al., 2014; Zhao et al., 2013b). However, a report by
Chenet al. challenged thevalidity of interactionsbetweenPGRN
and TNFR (Chen et al., 2013). In their paper, they claimed that
they could not detect the binding of their recombinant PGRN
protein to TNFR1/2 by using antibody pull-down and Biocore
methods. A letter-to-editor was published by the group that
originally reported PGRN-TNFR interactions, right after Chen
et al. paper was released (http://www.jneurosci.org/content/33/
21/9202.long/reply#jneuro_el_111445). In their response, they
listed several reasons to explain Chen’s inability to demonstrate
the interactions. First, the letter pointed out that the recombinant
PGRN produced by Chen et al. appeared to be problematic and
thedatageneratedwith theirproteinwere inconsistent indifferent
ﬁgures in the same paper. Second, an inappropriate chip, the
CM5 chip, was used in Chen’s surface plasmon resonance
assay. Proper selection of a chip is crucial for demonstrating
PGRN-TNFR binding activity because some matrices encoded
on the chips have been found to interfere with the interaction of
PGRNwith TNFR (Jian et al., 2013b). Even if the PGRN used in
theChenexperimentwassuitable, thePGRN-TNFRinteractions
would not have been observed in their SPR assay with the CM5
chip. Third, the Chen et al. paper used an improper positive
control, Sortilin, to demonstrate TNFR binding activities. PGRN
is a cysteine-rich protein and proper folding of the protein is
critical to mediate its binding to TNFR. Successful binding to
Sortilin (used as a positive control in Chen paper) is not a sufﬁ-
cient positive control to showPGRN-TNFR interactionsbecause
only the last threeQLLaminoacids ofPGRNare required to bind
to Sortilin (Zheng et al., 2011). The binding of PGRN to TNFR is
much more complicated, and three fragments separated by
other regions are needed to form a proper conformation to
maintain TNFR binding activity (Fig. 1) (Tang et al., 2011).
REINFORCEMENT OF PGRN-TNFR INTERACTIONS
BY THE LABORATORY THAT ORIGINALLY
REPORTED THE INTERACTIONS
Surface plasmon resonance (SPR) assay is a widely used
approach to demonstrate the direct interactions among






Figure 1. Domain structure and organization of PGRN.
Three fragments required for binding to TNFR (i.e. Atsttrin)
and the last three residues of PGRN (QLL) required for
Sortilin binding are indicated.
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macromolecules (Myszka, 1997). The type of equipment and
the selection of the chip are critical in general (Maynard
et al., 2009) as well as in the stoichiometry of TNF binding to
TNFR (Reis et al., 2011). These proper experiment condi-
tions also appear to be important for detecting the binding of
PGRN to TNFR. The binding of PGRN to TNFR was origi-
nally detected using the COOH1 chip, a planar PEG-based
chip, at SensiQ (Tang et al., 2011). This ﬁnding has now
been repeated with PGRN from Adipogen (Jian et al.,
2013b). However, no binding was observed using the
COOHV chip, a 3D Dextran chip. In addition, the CM5 chip
from Biocore (used in Chen’s paper (Chen et al., 2013)) did
not detect the binding of PGRN to TNFR either. In short, the
demonstration of interactions of PGRN-TNFR with SPR
appears to be highly dependent upon the type of chip used.
Matrix coated onto the chips, such as Dextran on COOHV
chip, appears to interfere with binding of PGRN to TNFR1
and TNFR2, but does not affect the binding of TNF-α to
TNFR (Fig. 2). Failure of the CM5 and COOHV chips to
show PGRN-TNFR binding may be related to their high
immobilization capacity, whereas a low capacity is preferable
for kinetic experiments (van der Merwe et al., 1993).
Sortilin was set as a positive control in Chen’s paper to
show that their recombinant PGRN had activity. As
discussed in the follow-up paper (Jian et al., 2013b), binding
to Sortilin is not sufﬁcient to show that PGRN has proper
folding, as PGRN binding to Sortilin only needs the last three
QLL amino acids in the C-terminal (Zheng et al., 2011).
Indeed, DTT treatment, known to disturb the conformation of
PGRN, completely abolished the binding activity of PGRN to
TNFR2. However, PGRN binding activity to Sortilin was
actually increased after DTT pretreatment (Fig. 3) (Jian et al.,
2013b), suggesting that QLL motifs at the C-terminus in the
denatured PGRN might become more easily accessible to
Sortilin (Fig. 1) (Jian et al., 2013b). Although addition of DTT
in the in vitro binding system completely abolished the
binding of PGRN to TNFR, it is noted that the PGRN/TNFR
interactions were ﬁrst detected in a yeast whose cytosol is
also reducing. These results suggest that DTT may create a
much stronger reducing condition, leading to the disruptions
of proper disulﬁde bonds in PGRN, when compared to the
physiological reducing conditions inside yeast cells. Addi-
tionally, some co-factors, such as chaperones known to bind
to PGRN (Almeida et al., 2011), may mitigate the negative
effects of reduced conditions on PGRN/TNFR interactions in
yeast.
Atsttrin, consisting of half Grn F-A-C domain, also binds to



















































































Figure 2. PGRN binds to TNFR on COOH1 chip, but not on COOHV chip in SensiQ surface plasmon resonance assay.
(A) TNF binds to TNFR1 (red line) and TNFR2 (blue line) in SensiQ COOHV chip. (B) PGRN fails to bind to both TNFR1 (red line) and
TNFR2 (blue line) on COOHV chip. (C) TNF-α binds to TNFR1α (red line) and TNFR2 (blue line) on COOH1 chip. (D) PGRN from
adipogen binds to both TNFR1 (red line) and TNFR2 on COOH1 (blue line) chip. Adapted from Jian J, et al, FEBS letters, 2013.
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inﬂammatory arthritis (Tang et al., 2011). It is speculated that
the three fragments in Atsttrin form a conformation that
mimics the trimer structure of TNF-α when binding to TNFR
(Tian et al., 2014b). If this is the case, the change of the
order in F-A-C should not affect the binding activity of Atsttrin
to TNFR. Given this, the original order of F-A-C (Atsttrin α)
was changed to A-C-F (Atsttrin β), or to A-F-C (Atsttrin γ)
(Tian et al., 2014b). All three forms of Atsttrin were found to
bind to TNFR in the yeast two-hybrid system. Interestingly,
recombinant Atsttrin β had similar binding activity to TNFR
as Atsttrin α in solid phase assay. Moreover, Atsttrin β also
had a therapeutic effect in inﬂammatory arthritis models
(Tian et al., 2014b).
CONFIRMATION OF PGRN-TNFR INTERACTIONS
IN VARIOUS DISEASES AND CONDITIONS BY
INDEPENDENT LABORATORIES
Although several papers, including aforementioned follow-up
studies to dissect the interaction between PGRN and TNFR
(Jian et al., 2013b; Tian et al., 2014b) and detailed
methodology (Tian et al., 2014a; Tian et al., 2012), were
published from the laboratory that ﬁrst reported the PGRN-
TNFR interactions (Tang et al., 2011), the controversy about
PGRN-TNFR interactions as presented by the Chen et al.
paper (Chen et al., 2013) persisted. The debate appears to
have ﬁnally been settled given the latest conﬁrmations of the
PGRN-TNFR interaction, as well as extensions of the inter-
action, in various diseases published by several indepen-
dent laboratories (Alquezar et al., 2015; Li et al., 2014; Liu
et al., 2014; Liu et al., 2015; Thurner et al., 2015; Wang et al.,
2015a). These are brieﬂy described below. In addition, the
physical and functional associations between PGRN/Atsttrin
and TNFR/DR3 as well as their interplays with TNF-α and
TL1A are summarized in Table 1.
PGRN and its derivative, Atsttrin, directly bind to TNFR
and DR3, and administration of Atsttrin effectively
ameliorated inﬂammation in mouse colitis model
The interaction between PGRN and its derivative, Atsttrin,
with TNFR was also conﬁrmed and extended by a recent
report that Atsttrin directly binds to TNFRSF25 (DR3) and
inhibits TNF-like ligand 1A (TL1A) activity (Liu et al., 2014).
This group screened the associations of Atsttrin with all
members of the TNFR subfamily, which led to the discovery
of TNFRSF25 (DR3), the highest homology to TNFR1
(Bodmer et al., 1997; Chinnaiyan et al., 1996; Croft, 2009),
as an additional Atsttrin-interacting member in the TNFR
family. Atsttrin inhibited the interaction between DR3 and its
TNF-like ligand 1A (TL1A). In addition, Atsttrin inhibited
TL1A-stimulated target gene expressions and neutralized
TL1A-enhanced osteoclastogenesis in vitro, and amelio-
rated the pathology in dextran sulfate sodium induced colitis
in vivo (Liu et al., 2014). The direct binding of Atsttrin to DR3
also led this group to examine whether or not PGRN also
directly binds to DR3. Their data revealed this was the case:
recombinant PGRN directly binds to DR3 in an ELISA-based
in vitro binding assay, as it did to TNFR2 (Fig. 4).
Direct binding between Atsttrin and TNFR2 is conﬁrmed
and quantiﬁed by a novel in vitro binding ﬂuorescence
assay
A novel GST pull-down-based ﬂuorescence assay was
developed by a group to detect and quantify the interaction
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Figure 3. DTT treatment of PGRN abolishes its binding to TNFR, whereas enhances its binding to Sortilin. (A) DTT treatment
disrupts the direct binding between PGRN and TNFR2. PGRN from Liu’s lab was pretreated with or without 10 mmol/L DTT, and
various amounts of PGRN, as indicated, were coated on the plate. Binding to TNFR2 was measured by solid phase assay. (B) DTT
treatment enhances the binding of PGRN to Sortilin. Similar to (A), same dosages of PGRN from Liu’s lab were pretreated with or
without 10 mmol/L DTT, the binding to Sortilin was measured. Adapted from Jian J, et al, FEBS letters, 2013.
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system, GST-fusion Atsttrin was expressed in E. coli and
puriﬁed by GST-glutathione beads. EYFP-fused TNFR2 was
expressed in mammalian cells. GST-Atsttrin fusion proteins
were ﬁrst incubated with TNFR2-EYFP fusion proteins. After
centrifugation, the complex was collected, and the interac-
tion between Atsttrin and TNFR2-EYFP was analyzed
Table 1. Physical and functional associations of PGRN/Atsttrin and TNFR/DR3 as well as their interplays with TNF-α and TL1A
Physical/Functional interactions Model/Methods References
In vitro direct binding assays
PGRN and Atsttrin directly bind to TNFR1 and TNFR2 SPR, ELISA-based binding Tang et al. (2011)
Tian et al. (2014a)
CRD2 and CRD3 of TNFR directly bind to PGRN SPR, ELISA-based binding Jian et al. (2013b)
PGRN and Atsttrin bind to TNFR2 and DR3 ELISA-based binding Liu et al. (2014)
CRD2 and CRD3 of TNFR2 inhibits the binding of PGRN to TNFR2 ELISA-based binding Li et al. (2014)
Changing the order of F, A, C doesn’t affect Atsttrin binding to TNFR ELISA-based binding Tian et al. (2014b)
GST-fusion Atsttrin directly binds to EYFP-fused TNFR2 GST-pull down assay Wang et al. (2015a)
In vivo interaction assays
PGRN associates with TNFR1 and TNFR2 in chondrocytes Co-IP Tang et al. (2011)
PGRN associates with TNFR2 in splenocytes Co-IP Jian et al. (2013b)
PGRN interacts with TNFR2 in chondrogenic ATDC5 cells Co-IP Li et al. (2014)
PGRN binds to TNFR and regulates WNT pathway in lymphocytes Co-IP Alquezar et al. (2015)
Phosphorylated PGRN at Serine 18 loses binding activity to TNFR
and DR3 in lymphoblastoid cells
Co-IP Thurner et al. (2015)
PGRN binds to TNFR1 and TNR2 in hepatocytes and adipocytes Co-IP Li et al. (2015)
Functional interplays with TNF and TL1A
PGRN blocks the TNF-α induced respiratory burst in neutrophils In vitro cell culture model Zhu et al. (2002)
PGRN and Atsttrin block TNF-induced inﬂammatory arthritis Inﬂammatory arthritis Tang et al. (2011)
PGRN reduces LPS-induced lung inﬂammation through TNFR2 Acute lung injury Guo et al. (2012)
PGRN promotes bone healing targeting TNF/TNFR signaling Ectopic bone formation Zhao et al. (2013a)
PGRN suppresses TNF-upregulated expression of ICAM-1 and
VCAM-1 in endothelial cells
Atherosclerosis Kawase et al. (2013)
PGNN protects ischemic-reperfusion brain injury, and directly blocks
TNF-binding to neutrophils as well as neutrophil migrations
Ischemic-reperfusion brain injury Egashira et al. (2013)
PGRN and Atsttrin have therapeutic effects to treat skin inﬂammation Dermatitis Zhao et al. (2013b)
PGRN and Atsttrin have protective role in DSS-induced colitis by
blocking TNF and TL1A
Chemical-induced colitis Wei et al. (2014a)
Liu et al. (2014)




Zhao et al. (2014)
Atsttrin ameliorates osteoarthritis development by blocking TNF-
upregulated matrix proteases and inﬂammatory factors
Surgically induced OA Xia et al. (2015)
3D printed Atsttrin scaffold promotes bone defect regeneration with
TNF/TNFR signaling involvement
Post-calvarial defect surgery Wang et al. (2015b)
PGRN induces insulin resistance through TNFR1 pathway Insulin resistance Li et al. (2015), Liu
et al. (2015)
PGRN decreases hypoxia-induced renal injury Ischemic-reperfusion kidney Zhou et al. (2015)
Patient data
PGRN overcomes TNF-α down-regulation of Treg suppressive
function and Foxp3 expression
PGRN autoantibodies, which provide an inﬂammatory environment,
is detected in several autoimmune diseases
Increased TNF-α activity in lymphocytes bearing FTLD GRN
mutations
Patients samples Tang et al. (2011)
Thurner et al. (2013a)
Thurner et al. (2013b)
Thurner et al. (2014)
Thurner et al. (2015)
Alquezar et al. (2015)
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through measuring the ﬂuorescence intensity. The interac-
tion between Atsttrin and TNFR2 was veriﬁed by the
detection of the ﬂuorescence after the GST-pull down. Using
this modiﬁed in vitro approach, this group not only conﬁrmed
the direct binding of Atsttrin to TNFR, but also presented a
more convenient and antibody-free assay that could be used
to precisely quantify the interactions between TNFR and
Atsttrin, and probably PGRN as well.
Atsttrin in a 3D-printed scaffold promotes bone healing
through targeting TNF/TNFR signaling
Recombinant PGRN protein accelerated bone formation
mainly depends on TNFR2, as PGRN has a negligible effect
in promoting bone formation in TNFR2 KO mice (Zhao et al.,
2013a). PGRN blocked TNF-α-induced inﬂammatory osteo-
clastogenesis and protected BMP-2-mediated ectopic bone
formation in TNF-α transgenic mice (Zhao et al., 2013a).
Very recently, PGRN-derived Atsttrin was also reported to
stimulate bone regeneration through inhibiting TNF signal-
ing. Brieﬂy, Atsttrin was incorporated into 3D-printed alginate
(Alg)/hydroxyapatite (nHAp) scaffolds, and these scaffold
implantations were used to stimulate bone regeneration
(Wang et al., 2015b). Atsttrin reduced the suppressive
effects of TNF-α on BMP-2-induced osteoblasts differentia-
tion and the 3D-printed Atsttrin-Alg/nHAp scaffold signiﬁ-
cantly decreased the number of TNF-α positive cells within
wound sites in a post-calvarial defect surgery model (Wang
et al., 2015b).
Intra-articular transplantation of Atsttrin-transduced
mesenchymal stem cells inhibit TNF-α-mediated
catabolic response and ameliorate osteoarthritis
development
It was reported that aged PGRN deﬁcient mice developed
osteoarthritis (OA)-like phenotype (Zhao et al., 2014), and
local injection of rPGRN into a surgically-induced OA model
had therapeutic effects (Zhao et al., 2014). This protective
function of PGRN in OA was independently reproduced by
PGRN-derived Atsttrin recently (Xia et al., 2015). Brieﬂy,
recombinant Atsttrin is expressed in genetically-modiﬁed
mesenchymal stem cells (named as MSC-Atsttrin), and
MSC-Atsttrin signiﬁcantly suppressed TNF-α-driven up-reg-
ulation of matrix proteases and inﬂammatory factors. Intra-
articular injection of MSC-Atsttrin prevented the progression
of degenerative changes in the surgically induced OA mouse
model (Xia et al., 2015), indicating that suppression of TNF-α
activity is an effective strategy for OA treatment and that
intra-articular injection of MSCs-Atsttrin could be a promising
therapeutic intervention.
PGRN inhibits ER stress-mediated apoptosis primarily
through interaction with TNFR2
PGRN was reported to play an important role in the ER
stress response (Li et al., 2014). PGRN-deﬁcient cells are
susceptible to ER stress-induced apoptosis, and recombi-
nant PGRN protein can rescue these cells from the ER
stress-triggered signal pathway and cell death. Although
PGRN was found to bind to both TNFR1 and TNFR2 in ER
stress by co-immunoprecipitation (Co-IP), PGRN-mediated
rescue was mainly through interaction with TNFR2 (Li et al.,
2014). The CRD2 and CRD3 domains of TNFR2 are known
to bind to PGRN (Jian et al., 2013b) as does to TNF-α.
Recombinant GST-fusion R2C2C3 protein completely
blocked PGRN binding to TNFR2 in a solid phase binding
assay and further abrogated PGRN-mediated protective
function in ER stress-induced cell death (Li et al., 2014).
PGRN binding to TNFR2 triggered protective signaling to
prevent cell death caused by ER stress. It is noted that this
group also conﬁrmed the direct interactions between PGRN
and TNFR in a solid phase binding assays with recombinant
proteins, in addition to the in vivo interactions, as assayed by
Co-IP.
PGRN binds to TNFR and regulates WNT5a expression
in peripheral blood lymphocytes from FTLD-linked GRN
mutation carriers
It is well established that GRN gene mutations are associ-
ated with various kinds of neurological degenerative dis-
eases, such as frontotemporal lobar dementia (FTLD),
Parkinson’s disease, Alzheimer’s disease, multiple sclerosis,
and amyotrophic lateral sclerosis (Baker and Manuelidis,














Figure 4. PGRN directly binds to DR3, examined by solid
phase binding assay. Various dose of PGRN was coated to
ELISA plate, biotinylated DR3, TNFR2 (serving as a positive
control) or BSA (serving as a negative control) was then added
to each well, bound protein was detected by adding avidin-HRP
to each well and the absorbance was measured at OD 450 nm.
Adapted from Liu C et al, PLoS ONE 2014.
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Vercellino et al., 2011). It is also believed that inﬂammation
plays an important role in the pathogenesis of these disor-
ders; however, why and how PGRN deﬁciency associates
with neuronal loss in various kinds of neurological degen-
erative disorders remains unknown. Very recently, Alquezar
et al. reported that PGRN deﬁcient cells showed increased
expression of Wnt5a that was associated with overactivation
of the NF-κB signaling (Alquezar et al., 2015). Speciﬁcally,
they demonstrated the physical binding of PGRN with TNFR
in lymphoblasts. The competitive nature between PGRN and
TNF for binding both TNFR1 and TNFR2 was also observed.
In addition, blocking TNF-activated NF-κB signaling, using
either wedelolactone or speciﬁc antibodies against TNFRs,
inhibited Wnt5a overexpression and proliferation seen in
PGRN-deﬁcient cells. In contrast, the activation of NF-κB
signaling by TNF increased Wnt5a-dependent proliferation
of control cells. Further, the overactivation of CDK6-associ-
ated kinase activity also contributed to the increase of
NF-κB-mediated transcription of Wnt5a. Collectively, these
results revealed an important role of NF-κB signaling in
PGRN-associated FTLD-TDP and conﬁrmed that PGRN
binds to TNF receptors to regulate the expression of Wnt5a.
These interesting ﬁndings not only provide new insights into
the mechanism underlying GRN mutations associated
FTLD-TDP, but also present PGRN as a potential, innova-
tive, therapeutic target for treating patients with GRN muta-
tions linked to a number of neurological degenerative
diseases, especially FTLD-TDP.
Ser81 of PGRN is critical for PGRN binding to TNFR
in patients with autoimmune diseases
More interestingly, the importance of PGRN-TNFR interac-
tions in autoimmune diseases was conﬁrmed with patient
samples in a series of studies. Progranulin autoantibody was
found in patients with psoriatic arthritis (Thurner et al., 2013b)
and patients positive for PGRN antibody were associated
with more complications such as enthesitis or dactylitis.
PGRN protective effects to TNF-induced apoptosis were
inhibited by this PGRN antibody (Thurner et al., 2013b). The
frequency of PGRN antibody was signiﬁcantly higher in many
types of autoimmune disorders, including variety of vasculitis,
systemic lupus erythematosus and rheumatoid arthritis,
compared with healthy control (Thurner et al., 2013a). PGRN
antibody was also found in inﬂammatory bowel diseases as
well (Thurner et al., 2014), including 16% of patients with
Crohn’s disease and 21% of patients with ulcerative colitis.
PGRN antibodies led to an increase of TNF-α-induced down-
modulation of FOXP3 in CD4+CD25hi Tregs (Thurner et al.,
2014). The PGRN antibody was found against an epitope of
hyper-phosphorylated Ser81 of PGRN (Thurner et al., 2015).
PKCβ1 was identiﬁed as the relevant kinase and PP1 as the
relevant phosphatase for phosphorylation and dephospho-
rylation of Ser81 of PGRN in patients with autoimmune dis-
eases, and hyperphosphorylated PGRN was found to lack its
binding activity to TNFR1, TNFR2 and DR3, and thereafter
lost anti-TNF functions. These important ﬁndings not only
conﬁrmed the PGRN-TNFR interaction in human samples,
but also indicated that certain modiﬁcations, in this case,
phosphorylation at Ser81, markedly affected the interactions
between PGRN and TNFR (Thurner et al., 2015).
PGRN-TNFR1 interaction is involved in insulin
resistance
The interaction between PGRN and TNFR is further ratiﬁed
by investigations into PGRN’s roles in insulin sensitivity.
PGRN has recently implicated in the regulation of glucose
metabolism and insulin sensitivity. PGRN was found to
induce impaired insulin sensitivity via its interaction with
TNFR1. Notably, TNFR1 blocking peptide-Fc fusion protein
was shown to block the interaction of PGRN with TNFR1 and
resulted in the restoration of insulin sensitivity, showing a
signiﬁcant relationship between PGRN and TNFR1 (Li et al.,
2015; Liu et al., 2015).
PGRN’S ANTI-TNF ACTION IN MULTIPLE
INFLAMMATORY CONTEXTS
The importance and validity of PGRN-TNFR interactions in
inﬂammatory diseases and conditions are supported by more
recent experimental and epidemiological evidences. In addi-
tion to musculoskeletal disorders, including inﬂammatory
arthritis (Tang et al., 2011; Tian et al., 2014b), osteoarthritis
(Zhao et al., 2014) and bone healing (Zhao et al., 2013a),
PGRN was also reported to play an important role in other
common inﬂammatory diseases (Table 1). For instance,
PGRN is involved in the pathogenesis in the inﬂammatory
bowel diseases. PGRN-deﬁcient mice are susceptible to DSS
and TNBS-induced colitis, whereas recombinant PGRN
ameliorated the pathology and reduced the histological score.
This therapeutic function is mediated through TNFR2 and
IL-10, as rPGRN lost its effect in TNFR2 deﬁcient colitis model
and its therapeutic effect could be blocked by neutralizing the
IL-10 antibody (Wei et al., 2014a; Wei et al., 2014b).
Expression of PGRN was signiﬁcantly upregulated in
response to oxazolone triggered skin inﬂammation (Zhao
et al., 2013b). PGRN deﬁcient mice have more severe
inﬂammation and stronger downstream activation of the TNF
signaling pathway. Atsttrin also shows its therapeutic effect
for the prevention and treatment of skin inﬂammation (Zhao
et al., 2013b). Similar results were also reported in another
TPA-induced psoriasis-like skin inﬂammation model (Huang
et al., 2015). PGRN expression was dramatically enhanced
in the effected lesions of TPA-treated WT mice and PGRN
deﬁcient mice were more sensitive to the TPA-induced skin
inﬂammation. The enhanced inﬂammation in PGRN KO mice
is likely to be resulted from reduced regulatory T cells in the
cervical lymph nodes (Huang et al., 2015). Furthermore,
serum level PGRN/TNF ratio is negatively related to disease
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severity in psoriasis patients (Thurner et al., 2013b). PGRN-
Abs are also detected with around 20% of psoriatic arthritis
patients and serum levels of PGRN are signiﬁcantly lower in
PGRN-Abs positive patients compared with PGRN-Abs
negative patient, indicating that this neutralizing PGRN Abs
provides a proinﬂammatory environment in psoriasis patients
(Thurner et al., 2013a; Thurner et al., 2013b).
In a LPS-induced acute lung injury model, intratracheal
administration of LPS causes severe lung inﬂammation and
subsequent animal death. PGRN shows remarkable reversal
of LPS-induced lung permeability, as assessed by reduc-
tions in total protein, albumin, and IgM in BAL ﬂuid (Guo
et al., 2012), as well as body weight loss. This function is
mediated through TNFR2, since neutralizing the antibody of
TNFR2, but not TNFR1, completely blocks PGRN thera-
peutic function (Guo et al., 2012).
In an ischemic-reperfusion brain injury model, expression
of PGRN was signiﬁcantly decreased after ischemic-reper-
fusion injury, and supplement rPGRN protein dramatically
protected neutrophil-mediated brain damage (Egashira
et al., 2013), as evidenced by neutrophil inﬁltration, reduced
levels of MMP-9, and NF-κB activation in PGRN treated
group in vivo (Egashira et al., 2013). PGRN directly blocks
TNF-binding to neutrophils as well as neutrophil migrations
in a dose-dependent manner (Egashira et al., 2013).
PGRN has protective functions in atherosclerosis, as
PGRN and ApoE double KO mice showed severe
atherosclerotic lesions compared with ApoE KO mice. This
protective function relies on PRGN anti-TNF function, as
PGRN suppresses TNF-upregulated expression of ICAM-1
and VCAM-1 in endothelial cells, two crucial adhesion
molecules that recruit inﬂammatory cells (Kawase et al.,
2013). In a similar study by Hwang et al., PGRN was shown
to protect vascular endothelium against atherosclerotic
inﬂammatory reaction via Akt/eNOS and NF-kB pathway.
PGRN signiﬁcantly reduced the expression of TNF-α and
MCP-1(Hwang et al., 2013).
PGRN is also involved in acute renal injury (Zhou et al.,
2015). PGRN-deﬁcient mice developed more severe renal
damage caused by in an ischemia/reperfusion model,
characterized by higher serum creatinine, increased tubular
epithelial cell death, and tubulointerstitial neutrophil and
macrophage inﬁltration when compared to WT mice (Zhou
et al., 2015). Recombinant PGRN protein decreased
hypoxia-induced inﬂammatory responses and apoptosis in
proximal tubule epithelial cells in vitro, and further prevent or
treat ischemia/reperfusion-induced renal injury in vivo when
administered before or after ischemia (Zhou et al., 2015).
Therefore, PGRN-based therapeutics might have applica-
tions in the treatment or prevention of acute kidney injury
(Tadagavadi and Reeves, 2015).
SUMMARY AND PERSPECTIVE
PGRN is an important endogenous anti-inﬂammatory mole-
cule that binds to three members in TNFR subfamily, i.e.
TNFR1, TNFR2, and DR3. PGRN and its derived Atsttrin
appear to exert their anti-inﬂammatory activities 1) by acti-
vation of PGRN/TNFR2 protective pathway through acting
as a new ligand of TNFR2, which is known to mediate
beneﬁcial and protective roles in joint destruction and
inﬂammatory processes (Aggarwal, 2014; Bluml et al., 2010;
Bluml et al., 2012; Faustman and Davis, 2010; McCann
et al., 2014), and 2) by inhibition of TNF/TNFR1 and TL1A/
DR3 inﬂammatory signaling through functioning as the
antagonist of TNF-α and TL1A (See proposed model in
Fig. 5).
The interactions between PGRN and TNFR have been
demonstrated by many laboratories in multiple disease
contexts, indicating that the balance of TNF-α/PGRN is
crucial to the development of these diseases. For instance,
etanercept (sTNFR2) has been known to be effective in
treating patients with rheumatoid arthritis (Scott, 2014), but
very recent paper showed that intra-articular injection of
sTNFR2 caused more severe joint destruction in a mouse
model of osteoarthritis (Kimmerling et al., 2015; Olson et al.,
2015). These paradoxical results may suggest the impor-
tance of PGRN-mediated protective role in the pathogenesis
Figure 5. A proposed model illustrating the multiple
signaling pathways by which PGRN (Atsttrin as well)
exerts its anti-inﬂammatory actions. PGRN (Atsttrin)
binds to TNFR2 and recruits unknown component, indi-
cated by “X”, to the receptor complex(s), followed by the
activation of anti-inﬂammatory pathway. In addition, PGRN
(Atsttrin) antagonizes TNF/TNFR1 and TL1A/DR3 signal-
ing and inhibits their inﬂammatory activities.
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of osteoarthritis. This is probably because of the fact that
sTNFR2 is not a TNF-α-speciﬁc inhibitor, and it is also a
PGRN blocker. Actually it probably inhibits PGRN much
more efﬁciently than does TNF-α, since PGRN exhibits an
approximately 600-fold higher binding afﬁnity to TNFR2 than
TNF-α (Tang et al., 2011). TNF-α is know to be dominance in
the pathogenesis of rheumatoid arthritis, and blocking TNF-α
with sTNFR2 is thus beneﬁcial to the patients with rheo-
maotid arthritis, whereas in the case of osteoarthritis, PGRN/
TNFR2 protective/anabolic pathway is likely to outweigh
TNF-α/TNFR inﬂammatory/catabolic signaling in regulating
osteoarthritis development, thus blocking both pathways
with sTNFR2 leads to more severe osteoarthritis. Interest-
ingly, blocking TNF-α action with its speciﬁc inhibitors, such
as inﬂiximab (mouse TNF-α monoclonal antibody) and
adalimumab (human TNF-α monoclonal antibody), were
reported to be protective for articular cartilage and subcon-
dral bone in animal osteoarthritis models (Ma et al., 2015;
Urech et al., 2010; Zhang et al., 2012). In addition, inﬂiximab
and adalimumab were also reported to signiﬁcantly alleviate
signs and symptoms in patients with osteoarthritis (Grunke
and Schulze-Koops, 2006; Maksymowych et al., 2012; Ver-
bruggen et al., 2012). The opposite effects of TNF-α speciﬁc
(i.e. inﬂiximab and adalimumab) and non-speciﬁc (i.e. etan-
ercept) inhibitors in osteoarthritis indicate the critical role of
other ligand(s) of TNFR, such as PGRN, in the regulation of
osteoarthritis.
The ﬁndings that PGRN is a new ligand and also an
antagonist of TNFR are in accordance with other examples
of ligand antagonism. One example is IL-1 receptor antag-
onist (IL-1RA). IL-1RA is a secreted protein that binds to
IL-1R and blocks IL-1 mediated signaling pathway (Conti,
1991), IL-1RA was reported to regulate IL-1 activity in vari-
ous inﬂammation diseases (Cavalli and Dinarello, 2015).
Another example is Argos, a secreted protein that is an
inhibitor of the epidermal growth factor receptor (EGFR)
pathway. Interestingly, the mechanism by which Argos
attenuates the EGFR pathway is by sequestration of ligand
and not by direct interaction with the receptor (Klein et al.,
2004; Klein et al., 2008). It appears that there exists an
intricate, and universal mechanism to control critical biolog-
ical and pathological activities by own naturally-occurring
antagonists.
In brief, the binding to TNFR of PGRN and its-derived
Atsttrin have been conﬁrmed and extended by the group that
originally reported the interactions, and also by numerous
independent groups. Cumulatively, these data also solidify
that PGRN, and especially Atsttrin, have potential to be the
next generation anti-inﬂammation drug candidates/targets.
ABBREVIATIONS
Co-IP, co-immunoprecipitation; EGFR, epidermal growth factor
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epithelin precursor; IL-1RA, IL-1 receptor antagonist; MCP-1,
monocyte chemoattractant protein-1; OA, osteoarthritis; PCDGF,
PC-cell derived growth factor; PEPI, proepithelin; PGRN,
progranulin; SPR, surface plasmon resonance; TNFR, tumor
necrosis factor receptors.
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